12 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14Primary· Day 14
Clinical status was derived from death, hospital discharge, and the ordinal scale as follows: score of "1" was used for all days on or after the date of death; score of "7" was used for all days on or after discharged alive date; last assessment carried forward for any missing values.The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or ECMO; 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COV
Score: 1
Group
Value
95% CI
Part A: Remdesivir (RDV) for 5 Days
8.0
Part A: Remdesivir for 10 Days
10.7
Score: 2
Group
Value
95% CI
Part A: Remdesivir (RDV) for 5 Days
8.5
Part A: Remdesivir for 10 Days
16.8
Score: 3
Group
Value
95% CI
Part A: Remdesivir (RDV) for 5 Days
4.0
Part A: Remdesivir for 10 Days
5.1
Score: 4
Group
Value
95% CI
Part A: Remdesivir (RDV) for 5 Days
9.5
Part A: Remdesivir for 10 Days
7.6
Score: 5
Group
Value
95% CI
Part A: Remdesivir (RDV) for 5 Days
6.0
Part A: Remdesivir for 10 Days
6.1
Score: 6
Group
Value
95% CI
Part A: Remdesivir (RDV) for 5 Days
4.0
Part A: Remdesivir for 10 Days
1.5
Score: 7
Group
Value
95% CI
Part A: Remdesivir (RDV) for 5 Days
60.0
Part A: Remdesivir for 10 Days
52.3
Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)Secondary· First dose date up to last dose date (maximum: 10 days) plus 30 days
Treatment-emergent Adverse Events (TEAE) were defined as AEs with onset dates on or after the study treatment start date and no later than 30 days after the permanent discontinuation of the study treatment and/or the AEs that led to premature discontinuation of study treatment.
Group
Value
95% CI
Part A: Remdesivir (RDV) for 5 Days
71.5
64.7 – 77.6
Part A: Remdesivir for 10 Days
75.1
68.5 – 81.0
Adverse events — posted to ClinicalTrials.gov
Time frame: Part A: First dose date up to the last dose date (maximum: 10 days) plus 30 days; Part B: First dose date up to the last dose date (maximum: 11 days) plus 30 days.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Part A: Remdesivir (RDV) for 5 Days
Serious: 43/200 (22%)
Deaths: 25/200
Part A: Remdesivir for 10 Days
Serious: 68/197 (35%)
Deaths: 28/197
Part B: Remdesivir for 10 Days (Mechanically Ventilated Group)
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
· Phase 2
· recruiting
NCT05911906 — An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
· Phase 4
· completed
NCT06860282 — A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects
· Phase 1
· completed
NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos
· Phase 4
· completed
NCT05780541 — PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
· Phase 3
· terminated
Other recruiting trials for COVID-19
Currently open trials in the same condition.
NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
· Phase 1
· active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
· Phase 3
· active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
· Phase 1
· recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
· Phase 2
· recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A
· Phase 3
· active not recruiting
Other Gilead Sciences trials
Trials by the same sponsor.
NCT07115368 — Study of GS-1219 in Participants With HIV-1
· Phase 1
· terminated
NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
· Phase 2
· terminated
NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain
· completed
NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
· Phase 2, PHASE3
· terminated
NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
· Phase 2
· terminated
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
Last refreshed: 31 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04292899.